Trial Profile

A prospective trial to evaluate the safety, tolerability and pharmacokinetics of a single intravenous dose of CB-181963 in healthy male subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CB 181963 (Primary)
Indications Gram-negative infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

05 Nov 2010 New trial record.
13 May 2003 According to a Cubist Pharmaceuticals media release, results of this trial were presented at the 13th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) 2003.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com